Patent ID: 8268317

Claim:
A method for treating a cancer, comprising administering a pharmaceutical composition to a subject with cancer, wherein the composition comprises a conjugate of a camptothecin drug and a targeting moiety of the formula: TM-[L3]-[L2]-[L1] m AA n -CPT, where TM is a cancer -targeting moiety selected from the group consisting of a murine, chimeric, primatized, humanized, and human monoclonal antibody (MAb), and said antibody is an intact antibody, an antibody fragment selected from the group consisting of Fab, Fab′, F(ab)2 and F(ab′)2, or a single-chain antibody; CPT is camptothecin or an analog thereof; L3 is a component of a cross-linker comprising a cyclohexane linked antibody-coupling moiety; L2 comprises a defined PEG with 1-12 monomeric units attach to L3 at one end with a triazole moiety, is attached to L1 at the other end by an amide, hydrazide, carbonate or ester bond, or to CPT by a carbonate bond when L1 and AA are absent, or attached to AA by an amide bond when L1 is absent; L1 comprises a collapsible linker, or a peptidase-cleavable moiety optionally attached to a collapsible linker, or an acid-cleavable moiety; AA is an amino acid; m is an integer with values of 0 or 1, and n is an integer with values of 0, 1, 2, 3, or 4; and when n is > 1 , the amino acids represented by AA can be the same or different; wherein the antibody or fragment thereof binds to a tumor-associated antigen (TAA).